全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Liuting Zeng , Kailin Yang
来源:[J].Journal of Ethnopharmacology(IF 2.755), 2017, Vol.199, pp.68-85
摘要:... Yanghe Decoction (YHD) is a Chinese medicine formula that is used to treat breast cancer, especially HER-positive breast cancer; however, the active compounds, potential targets, and pharmacological and molecular mechanism of its action against cancer remain unclear. Therefor...
作者:Tomas Baldassarre , Peter Truesdell , Andrew W. Craig
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)
摘要:Human epidermal growth factor receptor-2 (HER2) is amplified and a clinical target in a subset of human breast cancers with high rates of metastasis. Targeted therapies involving the antibody trastuzumab and trastuzumab-emtansine (T-DM1) have greatly improved outcomes for HER2-positive...
作者:G. Lopez-Vivanco , J. Salvador , R. Diez ...
来源:[J].Clinical and Translational Oncology(IF 1.276), 2017, Vol.19 (12), pp.1454-1461
摘要:To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer.
作者:Sinead Toomey , Alexander J. Eustace , Joanna Fay ...
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)
摘要:The Cancer Genome Atlas analysis revealed that somatic EGFR , receptor tyrosine-protein kinase erbB-2 ( ERBB2 ), Erb-B2 receptor tyrosine kinase 3 ( ERBB3 ) and Erb-B2 receptor tyrosine kinase 4 ( ERBB4 ) gene mutations (ERBB family mutations) occur alone or co-occur with somatic...
作者:Giampaolo Bianchini , Astrid Kiermaier , Giulia Valeria Bianchi ...
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)
摘要:NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal g...
作者:Darcie D. Seachrist , Steven T. Sizemore , Emhonta Johnson ...
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)
摘要:... The prognostic value of FST and its family members, the follistatin-like (FSTL) proteins, have been studied in various cancers. However, these studies, as well as limited functional analyses of the FSTL proteins, have yielded conflicting results on the role of these prot...
作者:Sara Olofsson , Hanna Norrlid , Eva Karlsson ...
来源:[J].The Breast(IF 2.491), 2016, Vol.29, pp.140-146
摘要:Abstract(#br)Introduction(#br)Trastuzumab is part of the standard treatment for HER2-positive breast cancer. The aim of this study was to estimate the societal value of trastuzumab administered through subcutaneous (SC) injection compared to intravenous (IV) infusion.(#br)Meth...
作者:Yoojin Chang , Kyong Hwa Park , Ji Eun Lee ...
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2018
摘要:Abstract(#br)The human epidermal growth factor receptor 2 (HER2)-positive breast cancer with overexpression of HER2 accounts for approximately 25% of breast cancers and is more aggressive than other types of breast cancer. Lapatinib has been widely used as a HER2-targeted therapy...
作者:Claudio Vernieri , Monica Milano , Marta Brambilla ...
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2019, Vol.139, pp.53-66
摘要:Abstract(#br)HER2-positive breast cancer (HER2 + BC) represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) directed against HER2 impressively improved pa...
作者:Xin Lu , Chundi Gao , Cun Liu ...
来源:[J].Pathology - Research and Practice(IF 1.213), 2019, Vol.215 (8)
摘要:Abstract(#br)Background(#br)The risk of brain metastasis (BM) in HER2-positive (+) breast cancer (BC) patients is significantly higher than that in HER2-negative (-) BC patients. The high incidence and mortality rate makes it urgent to elucidate the key pathways and genes involve...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×